Trial Profile
A Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinant Human Parathyroid Hormone [rhPTH(1-84)]
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2023
Price :
$35
*
At a glance
- Drugs Parathyroid hormone (Primary)
- Indications Hypoparathyroidism
- Focus Therapeutic Use
- Acronyms BALANCE
- Sponsors Shire; Shire Human Genetic Therapies; Takeda
- 07 Nov 2023 This trial has been completed in Portugal, according to European Clinical Trials Database record ( Date of the global end of the trial 2022-05-19).
- 23 May 2022 Status changed from recruiting to completed.
- 18 May 2022 Planned End Date changed from 10 May 2022 to 23 May 2022.